NCT00754728

"JACTAX" Trial Drug Eluting Stent Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 103 (actual)
• Sponsor: Boston Scientific Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Prospective, multi-center, non-randomized registry. 100 patients will be enrolled at up to 10 clinical sites in Europe. The results of this study will be compared to the TAXUS™ ATLAS clinical trial to evaluate the safety of the product.

Detailed description

The JACTAX Drug Eluting Stent has been designed to minimize the amount of polymer in contact with the vessel surface, thus potentially reducing the incidence of untoward side effects. The Juxtaposed Ablumenal Coating Process is capable of exclusive coating on the ablumenal side of pre-mounted bare metal stents. Juxtaposed Ablumenal Coating is a proprietary formulation containing a bioerodable polymer. The combination of the Juxtaposed Ablumenal Coating Process and Juxtaposed Ablumenal Coating create a unique microstructure surface, and reduces the amount of required polymer.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DEVICE	JACTAX DES	Drug Eluting Stent

Timeline

• Start date: 2007-07-01
• Primary completion: 2008-11-01
• Completion: 2010-01-01
• First posted: 2008-09-18
• Last updated: 2017-03-01

Locations

5 sites across 2 countries: Germany, United Kingdom